Resources / NITAG documentation

Evidence to Recommendations Framework: Clesrovimab

Download:

Abstract

Policy Question 

Should clesrovimab be recommended for all infants <8 months of age born during or entering their first RSV season?

  • Background paper
  • Americas
  • United States of America
  • RSV (Respiratory syncytial virus)
Loading...